Nerve growth factor

Jun 26, 2019

HKBU Discovers Mechanisms Underlying Early Life Stress and Irritable Bowel Syndrome

Jun 25, 2019

Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease

Mar 25, 2019

AlzeCure to Present at International Scientific Conference

Feb 19, 2019

Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain

Jan 03, 2019

Dompé announces first treatment with Oxervate(TM) eye drops (cenegermin-bkbj), for neurotrophic keratitis (NK)

Aug 22, 2018

Dompé receives FDA approval of Oxervate(TM) eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

Jul 20, 2017

Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompé Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy